These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23605807)

  • 1. What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data.
    Hu Y; Bajorath J
    AAPS J; 2013 Jul; 15(3):808-15. PubMed ID: 23605807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining the Degree of Promiscuity of Extensively Assayed Compounds.
    Jasial S; Hu Y; Bajorath J
    PLoS One; 2016; 11(4):e0153873. PubMed ID: 27082988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity profile relationships between structurally similar promiscuous compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing Molecular Promiscuity Evaluation Through Assay Profiles.
    Avram S; Curpan R; Bora A; Neanu C; Halip L
    Pharm Res; 2018 Oct; 35(11):240. PubMed ID: 30338400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth of ligand-target interaction data in ChEMBL is associated with increasing and activity measurement-dependent compound promiscuity.
    Hu Y; Bajorath J
    J Chem Inf Model; 2012 Oct; 52(10):2550-8. PubMed ID: 22978710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PubChem promiscuity: a web resource for gathering compound promiscuity data from PubChem.
    Canny SA; Cruz Y; Southern MR; Griffin PR
    Bioinformatics; 2012 Jan; 28(1):140-1. PubMed ID: 22084255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyzing compound activity records and promiscuity degrees in light of publication statistics.
    Hu Y; Bajorath J
    F1000Res; 2016; 5():. PubMed ID: 27347396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyzing Promiscuity at the Level of Active Compounds and Targets.
    Bajorath J
    Mol Inform; 2016 Dec; 35(11-12):583-587. PubMed ID: 27870240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.
    Dimova D; Hu Y; Bajorath J
    J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promiscuity progression of bioactive compounds over time.
    Hu Y; Jasial S; Bajorath J
    F1000Res; 2015; 4(Chem Inf Sci):118. PubMed ID: 26064479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How promiscuous are pharmaceutically relevant compounds? A data-driven assessment.
    Hu Y; Bajorath J
    AAPS J; 2013 Jan; 15(1):104-11. PubMed ID: 23090085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.
    Miljković F; Bajorath J
    J Comput Aided Mol Des; 2020 Jan; 34(1):1-10. PubMed ID: 31792884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of the PubChem BioAssay resource.
    Wang Y; Bolton E; Dracheva S; Karapetyan K; Shoemaker BA; Suzek TO; Wang J; Xiao J; Zhang J; Bryant SH
    Nucleic Acids Res; 2010 Jan; 38(Database issue):D255-66. PubMed ID: 19933261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Promiscuity Cliffs Using Machine Learning.
    Blaschke T; Feldmann C; Bajorath J
    Mol Inform; 2021 Jan; 40(1):e2000196. PubMed ID: 32881355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity cliffs in PubChem confirmatory bioassays taking inactive compounds into account.
    Hu Y; Maggiora GM; Bajorath J
    J Comput Aided Mol Des; 2013 Feb; 27(2):115-24. PubMed ID: 23296990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PubChem Substance and Compound databases.
    Kim S; Thiessen PA; Bolton EE; Chen J; Fu G; Gindulyte A; Han L; He J; He S; Shoemaker BA; Wang J; Yu B; Zhang J; Bryant SH
    Nucleic Acids Res; 2016 Jan; 44(D1):D1202-13. PubMed ID: 26400175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Promiscuity Relationship Puzzles-Extensively Assayed Analogs with Large Differences in Target Annotations.
    Hu Y; Jasial S; Gilberg E; Bajorath J
    AAPS J; 2017 May; 19(3):856-864. PubMed ID: 28265982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we discover pharmacological promiscuity early in the drug discovery process?
    Peters JU; Hert J; Bissantz C; Hillebrecht A; Gerebtzoff G; Bendels S; Tillier F; Migeon J; Fischer H; Guba W; Kansy M
    Drug Discov Today; 2012 Apr; 17(7-8):325-35. PubMed ID: 22269136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs.
    Hu Y; Bajorath J
    J Chem Inf Model; 2010 Dec; 50(12):2112-8. PubMed ID: 21070069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying the tendency of therapeutic target proteins to bind promiscuous or selective compounds.
    Hu Y; Bajorath J
    PLoS One; 2015; 10(5):e0126838. PubMed ID: 26000736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.